Table 3

Clinical outcomes in cohorts with conservative or surgery treatment, according to NT-proBNP tertiles

1-Year death30-Day death
No. of events/total patients (%)*HR (95% CI)P valueNo. of events/total patients (%)OR (95% CI)P value
Conservative†
 T1 (≤155.0)44/62 (71.0)Reference43/62 (69.4)Reference
 T2 (155.0–671.4)77/106 (72.6)1.00 (0.69 to 1.45)0.9975/106 (70.8)1.07 (0.54 to 2.12)0.85
 T3 (>671.4)105/137 (76.6)1.05 (0.74 to 1.49)0.7998/137 (71.5)1.10 (0.58 to 2.14)0.75
Surgery†
 T1 (≤155.0)6/214 (2.8)Reference4/214 (1.9)Reference
 T2 (155.0–671.4)13/171 (7.6)2.79 (1.06 to 7.33)0.048/171 (4.7)2.58 (0.76 to 8.70)0.13
 T3 (>671.4)11/139 (7.9)2.89 (1.07 to 7.81)0.045/139 (3.6)1.96 (0.52 to 7.43)0.32
  • *Values are Kaplan-Meier estimated rates.

  • P for interaction for the risk of 1-year death: NT-proBNP tertiles and treatment strategy (conservative or surgery) = 0.04; P for interaction for the risk of 30-day death: NT-proBNP levels (low or high) and treatment strategy (conservative or surgery) = 0.18.

  • NT-proBNP, N-terminal pro-brain natriuretic peptide.